Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Tables)

v3.19.2
Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2019
Accounting Policies [Abstract]  
Schedule of fair value on a nonrecurring basis
    Quoted Price in Active Markets for Identical Assets
(Level 1)
    Significant Other Observable Inputs
(Level 2)
    Significant Unobservable Inputs
(Level 3)
    Balance at
June 30, 2019
    Impairment Loss  
Patents and other technologies   $ -     $ -     $ 1,091,903     $ 1,091,903     $    -  

  

    Quoted Price in Active Markets for Identical Assets
(Level 1)
    Significant Other Observable Inputs
(Level 2)
    Significant Unobservable Inputs
(Level 3)
    Balance at December 31,
2018
    Impairment
Loss
 
Patents and other technologies   $ -     $ -     $ 1,255,689     $ 1,255,689     $ -  

 

Schedule of cash balances by geographic area
Country:   June 30, 2019     December 31, 2018  
United States   $ 2,761,051       81.2 %   $ 1,035,802       46.0 %
China     640,253       18.8 %     1,216,485       54.0 %
Total cash   $ 3,401,304       100.0 %   $ 2,252,287       100.0 %
Schedule of reconciliation of basic and diluted net loss per share
    Three Months Ended     Six Months Ended  
    June 30,     June 30,  
    2019     2018     2019     2018  
Net loss available to Avalon GloboCare Corp. common shareholders for basic and diluted net loss per share of common stock   $ (4,357,224 )   $ (1,294,394 )   $ (8,763,040 )   $ (2,775,973 )
Weighted average common stock outstanding - basic and diluted     75,183,354       71,979,678       74,437,336       71,122,356  
Net loss per common share attributable to Avalon GloboCare Corp. common shareholders - basic and diluted   $ (0.06 )   $ (0.02 )   $ (0.12 )   $ (0.04 )
Schedule of the effect of including these potential shares was antidilutive

 

    Three Months Ended
June 30,
    Six Months Ended
June 30,
 
    2019     2018     2019     2018  
Stock options     5,070,000       2,610,000       5,070,000       2,610,000  
Warrants     1,714,288       578,891       1,714,288       578,891  
Potentially dilutive securities     6,784,288       3,188,891       6,784,288       3,188,891